Posts Tagged ‘HIV’




Cells Grown By Japanese Researchers Kills Cancer

A team of researchers from both the University of Tokyo and the Riken Research Centre for Allergy and Immunology may have found a cure for HIV and Cancer. The research team was able to “extract live T-cells, the vital powerhouses of the human immune system, from patients, specifically targeting specialized cytotoxic T-cells which have the ability to recognize and attack signs of infection.  Researchers then converted the T-cells back to induced pluripotent stem cells (iPS) by exposing them to a group of compounds called the “Yamanaka factors,” in part so they could study the stem cells’ differentiation processes. Then the team reconverted the stem cells back into specialized disease-fighters, the T-cells known as “killer T-cells”or “killer T lymphocytes.” Among other critical findings, researchers discovered that the skin-cancer fighting T-cells remained capable of producing the crucial anti-tumor compound interferon.

“Stem cells can be grown at a much faster pace in a laboratory than in the human body, enabling researchers to create killer T lymphocytes that are—at least theoretically—ready for therapeutic human injection.”

“While the iPS cells did reconvert back into their original specializations, it’s unsure whether lab-grown cells will behave similarly to the immune system’s own disease-fighters when injected into the human body. Furthermore, the risk of rejection is high when cells from one patient are grown and converted for use in another.  Perhaps most importantly, it’s hard to predict whether cells that fight cancer in the lab will restrict their deadly effects to cancer cells in the body. Lead researcher Hiroshi Kawamoto, in a press release from the Riken Center, states, “the next step will be to test whether these T cells can selectively kill tumor cells but not other cells in the body.” It’s possible that lab-grown cells could attack normal, healthy human cells after therapeutic injection.  But medical and scientific experts remain cautiously optimistic.

“A lot of work needs to be done before we can think about clinical trials, but the initial data are promising.” Said Dr. Dusko Ilic, Senior Lecturer in Stem Cell Science, King’s College London.

The main challenge researchers face is the cost of producing large amounts of killer T lymphocytes safely. Numerous expensive confirmatory studies and trials will need to be conducted before the new therapy is approved for human use.

“The implications for the health of humankind, on the other hand, are immediate, and clear. If science has indeed provided a novel means of fighting our most persistent and deadly infections, untold amounts of suffering could be mitigated—and, ultimately, eradicated.”





“In two separate papers contained in the January 4th issue of the Cell Press Journal, Scientists in Japan have used old immune T-cells and regenerated them into T-cells that multiplied in greater numbers, had longer life spans and showed a greater ability to target diseased cells in HIV-infected cells and cancer cells. These discoveries could lead to more effective immune therapies.”


The human body contains immune cells programmed to fight cancer and viral infections, but they often have short life spans and are not numerous enough to overcome attacks by particularly aggressive malignancies or invasions.

The techniques the groups employed involved using known factors to revert mature immune T cells into induced pluripotent stem cells (iPSCs), which can differentiate into virtually any of the body’s different cell types. The researchers then expanded these iPSCs and later coaxed them to re-differentiate back into T cells. Importantly, the newly made T cells were “rejuvenated” with increased growth potential and lifespan, while retaining their original ability to target cancer and HIV-infected cells. These findings suggest that manipulating T cells using iPSC techniques could be useful for future development of more effective immune therapies.

In one study, investigators used T cells from an HIV-infected patient. The re-differentiated cells they generated had an unlimited lifespan and contained long telomeres, or caps, on the ends of their chromosomes, which protect cells from aging. This is significant because normal aging of T cells limits their expansion, making them inefficient as therapies. “The system we established provides ‘young and active’ T cells for adoptive immunotherapy against viral infection or cancers,” says senior author Dr. Hiromitsu Nakauchi, of the University of Tokyo.

The other research team focused on T cells from a patient with malignant melanoma. The re-differentiated cells they created recognized the protein MART-1, which is commonly expressed on melanoma tumors. “The next step we are going to do is examine whether these regenerated T cells can selectively kill tumor cells but not other healthy tissues. If such cells are developed, these cells might be directly applied to patients,” says senior author Dr. Hiroshi Kawamoto, of the RIKEN Research Center for Allergy and Immunology. “This could be realized in the not-so-distant future.”


Related articles

Two More Patients HIV-Free After Bone Marrow Transplants – ABC News

In VICTORIES & SUCCESS STORIES on September 12, 2012 at 5:08 pm

Read the story on the first man to recover from HIV Positive with a stem cell transplant who is now symptom free for 5 years! https://repairstemcell.wordpress.com/2010/12/10/man-appears-free-of-hiv-after-stem-cell-transplant-for-3-years/

And with these 2 more men now HIV free, perhaps the dream of an HIV Free Generation is one step closer to reality!

Two More Patients HIV-Free After Bone Marrow Transplants

Researchers at Brigham and Women’s Hospital in Boston have discovered that, following bone marrow transplants, two men no longer have detectable HIV in their blood cells.

The finding is significant because it suggests that by giving these patients transplants while they were on anti-retroviral therapy, they may have been cured of the AIDS-causing virus.

“We expected HIV to vanish from the patients’ plasma, but it is surprising that we can’t find any traces of HIV in their cells,” said Dr. Timothy Henrich, one of the researchers studying the two men. “It suggests that under the cover of anti-retroviral therapy, the cells that repopulated the patient’s immune system appear to be protected from becoming re-infected with HIV.”…

Two More Patients HIV-Free After Bone Marrow Transplants – ABC News

Engineered stem cells seek out and kill HIV infection in living organisms

In VICTORIES & SUCCESS STORIES on April 15, 2012 at 1:52 pm

“…stem cells can be genetically engineered into HIV-fighting cells…”

is there anything they can’t do???


Engineered stem cells seek out and kill HIV infection in living organisms

Washington, Sun, 15 Apr 2012 ANI

Washington, Apr 15 (ANI): In a new study, scientists have expanded on previous research that had provided proof-of-principal that human stem cells can be genetically engineered into HIV-fighting cells.

This time, they have demonstrated that these cells can actually attack HIV-infected cells in a living organism.

The study by UCLA researchers demonstrate for the first time that engineering stem cells to form immune cells that target HIV is effective in suppressing the virus in living tissues in an animal model.

“We believe that this study lays the groundwork for the potential use of this type of an approach in combating HIV infection in infected individuals, in hopes of eradicating the virus from the body,” Scott G. Kitchen, lead investigator of the study, said.

In the previous research, the scientists took CD8 cytotoxic T lymphocytes – the “killer” T cells that help fight infection – from an HIV-infected individual and identified the molecule known as the T cell receptor, which guides the T cell in recognizing and killing HIV-infected cells.

However, these T cells, while able to destroy HIV-infected cells, do not exist in great enough quantities to clear the virus from the body. So the researchers cloned the receptor and used this to genetically engineer human blood stem cells.


They then placed the engineered stem cells into human thymus tissue that had been implanted in mice, allowing them to study the reaction in a living organism.

The engineered stem cells developed into a large population of mature, multi-functional HIV-specific CD8 cells that could specifically target cells containing HIV proteins.

The researchers also discovered that HIV-specific T cell receptors have to be matched to an individual in much the same way an organ is matched to a transplant patient.

In this current study, the researchers similarly engineered human blood stem cells and found that they can form mature T cells that can attack HIV in tissues where the virus resides and replicates. They did so by using a surrogate model, the humanized mouse, in which HIV infection closely resembles the disease and its progression in humans.

In a series of tests on the mice’s peripheral blood, plasma and organs conducted two weeks and six weeks after introducing the engineered cells, the researchers found that the number of CD4 “helper” T cells – which become depleted as a result of HIV infection – increased, while levels of HIV in the blood decreased.

CD4 cells are white blood cells that are an important component of the immune system, helping to fight off infections. These results indicated that the engineered cells were capable of developing and migrating to the organs to fight infection there.

The researchers did note a potential weakness with the study: Human immune cells reconstituted at a lower level in the humanized mice than they would in humans, and as a result, the mice’s immune systems were mostly, though not completely, reconstructed.

Due to this, HIV may be slower to mutate in the mice than in human hosts. So the use of multiple, engineered T cell receptors may be one way to adjust for the higher potential for HIV mutation in humans.

“We believe that this is the first step in developing a more aggressive approach in correcting the defects in the human T cell responses that allow HIV to persist in infected people,” Kitchen added.

The study has been published in the journal PLoS Pathogens. (ANI)

Engineered stem cells seek out and kill HIV infection in living organisms.

Man appears free of HIV after stem cell transplant – FOR 3 YEARS!

Man appears free of HIV after stem cell transplant – FOR 5 YEARS! …and now there are TWO MORE HIV FREE PATIENTS!!!
UPDATE TO STORY!!  Jul 26, 2012 3:06pm
Two More Patients HIV-Free After Bone Marrow Transplants




  1. 42 year old man has leukemia.
  2. 42 year old man also has HIV.
  3. Man needs bone marrow transplant for leukemia.
  4. Creative doctor uses bone marrow from “retrovirus resistant” donor (the donor can NOT get HIV due to a genetic mutation).
  5. Procedure costs about $150,000 (“retrovirus resistant” donors are very rare and very hard to find).
  6. 42 year old man’s body “TAKES ON” the retrovirus resistance from the donor’s bone marrow.
  7. 42 year old man’s symptoms go away and stay away for one year, two years, 3 years, 4 years  next month.
  8. 42 year old man is now a 46 year old man with no leukemia and no HIV to be found in his body.


  • Doctors have not been able to detect the virus in his blood since about Jan of 2007.
  • In this case, there were 80 compatible blood donors living in Germany and on the 61st sample tested, they found one with the “retrovirus resistant” mutation from both parents.
  • There were no embryonic stem cells involved in this.  The stem cells in bone marrow are adult stem cells only.  Any time you see the words “treated” or “improved” or “recovered” associated with the words “stem cells”, assume it was from adult or repair stem cells until proven otherwise. https://repairstemcell.wordpress.com/stem-cells-for-newbies/




HISTORY OF THIS STORY (scroll down for full articles below)

  1. The original article that got almost no coverage is from Wall Street Journal – Nov 2008
  2. This article was then posted here in Feb 2009https://repairstemcell.wordpress.com/2009/02/20/stem-cells-hiv-part-2-a-doctor-a-mutation-and-a-potential-cure-for-aids-wsjcom/
  3. The abstract of the case was posted in the New England Journal of Medicine in Feb 2009 – See abstract below
  4. One of the most recent articles was in foxnews.com Dec 2010



A Doctor, a Mutation and a Potential Cure for AIDS – A Bone Marrow Transplant to Treat a Leukemia Patient Also Gives Him Virus-Resistant Cells; Many Thanks, Sample 61

“A 42-year-old HIV patient with leukemia appears to have no detectable HIV in his blood and no symptoms after a stem cell transplant from a donor carrying a gene mutation that confers natural resistance to the virus that causes AIDS, according to a report published Wednesday in the New England Journal of Medicine.”


The startling case of an AIDS patient who underwent a bone marrow transplant to treat leukemia is stirring new hope that gene-therapy strategies on the far edges of AIDS research might someday cure the disease.

The patient, a 42-year-old American living in Berlin, is still recovering from his leukemia therapy, but he appears to have won his battle with AIDS. Doctors have not been able to detect the virus in his blood for more than 600 days, despite his having ceased all conventional AIDS medication. Normally when a patient stops taking AIDS drugs, the virus stampedes through the body within weeks, or days.

[Dr. Gero Hutter]
Sixten Koerper
Dr. Gero Hütter isn’t an AIDS specialist, but he ‘functionally cured’ a patient, who shows no sign of the disease.

“I was very surprised,” said the doctor, Gero Hütter.

The breakthrough appears to be that Dr. Hütter, a soft-spoken hematologist who isn’t an AIDS specialist, deliberately replaced the patient’s bone marrow cells with those from a donor who has a naturally occurring genetic mutation that renders his cells immune to almost all strains of HIV, the virus that causes AIDS.


THE December 14, 2010 STORY

Doctors Claim HIV-Positive Man Cured by Stem Cell Transplant

Published December 14, 2010 – | FoxNews.com

There’s an estimated 33 million people worldwide living with HIV/AIDS, and now doctors believe one of them may have been cured of the virus after receiving a stem cell transplant in 2007, the medical journal Blood reported.

Timothy Ray Brown, an HIV-positive American living in Germany, had leukemia and was undergoing chemotherapy, when he received a transplant of stem cells from a donor carrying a rare, inherited gene mutation that seems to make carriers virtually immune to HIV infection.

The transplant appeared to wipe out both diseases, giving hope to doctors, but Dr. Anthony Fauci, director of the National Institutes of Allergy and Infectious Diseases, who has been studying HIV/AIDS for almost 30 years, said while this is an interesting proof of concept, it’s absurdly impractical.

“It’s hard enough to get a good compatible match for a transplant like this,” Fauci told FoxNews.com, “But you also have to find compatible donor that has this genetic defect, and this defect is only found in 1 percent of the Caucasian population and zero percent of the black population. This is very rare.”

Fauci said while this patient is “functionally cured” this is not something you can do with every HIV-infected individual.

“This is not prime time to me at all,” he said. “This is a very unusual situation that has little practical application for a simple reason. This donor not only had to be a good compatible match, but the donor had to have a genetic defect of cells that do not express the receptor that the HIV virus needs to enter the cell.”

Fauci also pointed to the fact that this transplant process is not only expensive, it’s incredibly painful and complicated, and requires the patient to start a whole new regimen of drugs.

“This patient is trading one poison for another. He may not have to be on antiretroviral drugs anymore, but he has to take immunosuppressant drugs now to prevent the rejection of his transplant cells. Again, what this is, is an interesting proof of concept, but it’s absolutely impractical.”

Dr. Thomas Quinn, director of Johns Hopkins Center for Global Health told FoxNews.com that he is very familiar with the “Berlin patient” case.

“This was a new report that looked much deeper into whether HIV could still be present or lurking in the body in some way, not cured, and since the transplant he remains viral free and his cells appear to be resistant to infection,” he said.

Quinn said he agrees with the researchers on this case that it would be qualified as the first HIV cure, opening the door to alternative means of curing HIV.

“He [Brown] has been without therapy for three years and appears to be free of the virus,” he said. “It gives hope to the millions of people infected with HIV that cure is a feasible option in the future.”

Even though Brown’s procedure proved to be successful, Quinn also warns that this was a rare case and a bone marrow transplant is not a cure-all for other HIV patients.

“It is a near fatal procedure that he had to have done because of the leukemia, but this procedure is very expensive and you have to be transplanted with a donor who is shown to be already resistant to HIV,” Quinn said. “You’re asking for a tall order to replicate this in the future.”

Brown’s case was published in a February 2009 issue of the New England Journal of Medicine

Read more: http://www.foxnews.com/health/2010/12/14/doctors-claim-hiv-positive-man-cured-stem-cell-transplant/#ixzz18Cug4Euz



Volume 360:692-698  February 12, 2009  Number 7

Long-Term Control of HIV by CCR5 Delta32/Delta32 Stem-Cell


Gero Hütter, M.D., Daniel Nowak, M.D., Maximilian Mossner, B.S., Susanne Ganepola, M.D., Arne Müßig, M.D., Kristina Allers, Ph.D., Thomas Schneider, M.D., Ph.D., Jörg Hofmann, Ph.D., Claudia Kücherer, M.D., Olga Blau, M.D., Igor W. Blau, M.D., Wolf K. Hofmann, M.D., and Eckhard Thiel, M.D.


Infection with the human immunodeficiency virus type 1 (HIV-1)requires the presence of a CD4 receptor and a chemokine receptor,principally chemokine receptor 5 (CCR5). Homozygosity for a32-bp deletion in the CCR5 allele provides resistance againstHIV-1 acquisition. We transplanted stem cells from a donor whowas homozygous for CCR5 delta32 in a patient with acute myeloidleukemia and HIV-1 infection. The patient remained without viralrebound 20 months after transplantation and discontinuationof antiretroviral therapy. This outcome demonstrates the criticalrole CCR5 plays in maintaining HIV-1 infection.
Source Information

From the Department of Hematology, Oncology, and Transfusion Medicine (G.H., D.N., M.M., S.G., A.M., O.B., I.W.B., W.K.H., E.T.) and the Department of Gastroenterology, Infectious Diseases, and Rheumatology (K.A., T.S.), Campus Benjamin Franklin; and the Institute of Medical Virology, Campus Mitte (J.H.) — all at Charité Universitätsmedizin Berlin; and the Robert Koch Institute (C.K.) — all in Berlin.

Drs. Hofmann and Thiel contributed equally to this article.

Address reprint requests to Dr. Hütter at Medical Department III Hematology, Oncology, and Transfusion Medicine, Charité Campus Benjamin Franklin, Hindenburgdamm 30 D-12203 Berlin, Germany, or at gero.huetter@charite.de// <!–[CDATA[–>
var u = “gero.huetter”, d = “charite.de”; document.getElementById(“em0”).innerHTML = ‘‘ + u + ‘@’ + d + ”
// ]]>.

Full Text of this Article

This article has been cited by other articles:

  • Arababadi, M. K., Hassanshahi, G., Azin, H., Salehabad, V. A., Araste, M., Pourali, R., Nekhei, Z. (2010). No Association Between CCR5-{Delta}32 Mutation and Multiple Sclerosis in Patients of Southeastern Iran. Lab Med 41: 31-33 [Abstract] [Full Text]
  • Fauci, A. S., Folkers, G. K. (2009). Investing To Meet The Scientific Challenges Of HIV/AIDS. Health Aff (Millwood) 28: 1629-1641 [Abstract] [Full Text]
  • Bonsignori, M., Moody, M. A., Parks, R. J., Holl, T. M., Kelsoe, G., Hicks, C. B., Vandergrift, N., Tomaras, G. D., Haynes, B. F. (2009). HIV-1 Envelope Induces Memory B Cell Responses That Correlate with Plasma Antibody Levels after Envelope gp120 Protein Vaccination or HIV-1 Infection. J. Immunol. 183: 2708-2717 [Abstract] [Full Text]
  • Levy, J. A. (2009). The Unexpected Pleiotropic Activities of RANTES. J. Immunol. 182: 3945-3946 [Full Text]
  • (2009). All you need to read in the other general journals. BMJ 338: b627-b627 [Full Text]
  • (2009). Stem-Cell Transplantation Enables Long-Term HIV Control. AIDS Clin Care 2009: 1-1 [Full Text]
  • Levy, J. A. (2009). Not an HIV Cure, but Encouraging New Directions. NEJM 360: 724-725 [Full Text]

From http://content.nejm.org/cgi/content/short/360/7/692

Scientists discover antibody that kills 91 percent of HIV – SmartPlanet

In VICTORIES & SUCCESS STORIES on July 11, 2010 at 11:47 am

Scientists discover antibody that kills 91 percent of HIV

By Andrew Nusca | Jul 8, 2010

Paving the way for an AIDS vaccine, scientists have discovered two potent antibodies, the strongest of which can neutralize 91 percent of HIV strains.

Researchers from the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases discovered the antibodies in the cells of a 60-year-old African-American gay man, whose body made the antibodies naturally.

“We have used our knowledge of the structure of a virus—in this case, the outer surface of HIV—to refine molecular tools that pinpoint the vulnerable spot on the virus and guide us to antibodies that attach to this spot, blocking the virus from infecting cells,” VRC director Gary Nabel said in a statement.

Last year, an HIV vaccine demonstrated roughly 30 percent efficacy. This new discovery triples the potency.

The announcement comes just over a week before the International AIDS Conference in Vienna.

The scientists found the antibodies, named VRC01 and VRC02, using a molecular device they developed — an HIV protein that the scientists modified so it would react only with antibodies specific to the site where the virus binds to cells it infects.

The researchers were able to determine the atomic-level structure of VRC01 when it’s attached to HIV, allowing them to design components of a potential vaccine that could teach the human immune system to make similar antibodies that could feasibly prevent infection by the vast majority of HIV strains worldwide.

The United Nations has estimated that more than 33 million people had HIV in 2008. An estimated 2.7 million contracted the virus that year.

Led by NIAID scientists Peter Kwong, John Mascola, and Gary Nabel, the research team screened some 25 million cells to discover 12 that produced the antibodies, reports the Wall Street Journal.

One question is whether scientists will be able to successfully use the antibodies to develop a vaccine to protect against AIDS.

Another is how quickly the antibodies can influence the human body to produce its own. It’s entirely possible that they could take months or years — another hurdle.

For now, the researchers plan to test the new antibodies in several ways. According to the Journal report, that includes:

  • Directly administering them like a drug;
  • Applying them as a “microbicide” gel before sexual intercourse;
  • Boosting an infected patient’s existing drug regimen.

To begin walking down that path, the VRC has contracted with a company to produce an antibody that’s safe for humans.

“Antibodies are like people: every single one is unusual in its own specific way,” said VRC structural biologist Peter Kwong to Nature. “These antibodies are freaks of nature.”

The research was published Thursday in the online edition of the journal Science.

via Scientists discover antibody that kills 91 percent of HIV – SmartPlanet.

Novel stem cell therapy to tackle HIV – dnaindia.com

In ALL ARTICLES on April 2, 2010 at 3:02 am

Novel stem cell therapy to tackle HIV

Thursday, April 1, 2010 14:40 IST

Washington, DC: A novel stem cell therapy could in the future be used to treat HIV, say researchers.

Researchers are studying a new approach that arms the immune system with an intrinsic defence against HIV.

While speaking at the Society for General Microbiology’s spring meeting in Edinburgh, Professor Ben Berkhout explained how this new approach could dramatically improve the quality of life and life expectancy for HIV sufferers in whom antiviral drugs are no longer effective.

In the absence of an effective vaccine, daily administration of anti-retroviral drugs is the most effective treatment for HIV. However, low patient compliance rates combined with the virus’s ability to easily mutate has led to the emergence of drug-resistant strains that are difficult to treat.

Professor Berkhout from the University of Amsterdam is investigating a novel gene therapy that has long-lasting effects even after a single treatment. It involves delivering antiviral DNA to the patients’ own immune cells that arms them against viral infection. “This therapy would offer an alternative for HIV-infected patients that can no longer be treated with regular antivirals,” he suggested.

The therapy involves extracting and purifying blood stem cells from the patient’s bone marrow. Antiviral DNA is transferred to the cells in the laboratory, after which the cells are re-injected into the body. The DNA encodes tiny molecules called small RNAs that are the mirror image of key viral genes used by HIV to cause disease. The small RNAs float around inside the immune cell until they encounter viral genes which they can stick to like Velcro(tm). This mechanism, called ‘RNA interference’ can block the production of key viral components from these genes.

Transferring the antiviral DNA to stem cells would help to restore a large part of the patient’s immune system. “Stem cells are the continually dividing ‘master copy’ cells from which all other immune cells are derived. By engineering the stem cells, the antiviral DNA is inherited by all the immune cells that are born from it,” explained Professor Berkhout.

via Novel stem cell therapy to tackle HIV – dnaindia.com.


In VICTORIES & SUCCESS STORIES on March 10, 2010 at 11:41 pm
Don’t miss any important stem cell news! Follow me on twitter! http://twitter.com/stemcellblogger
“Institute director Jan Nolta says UC Davis is moving away from the use of embryonic stem cells in favor of other techniques.”


First of dozen Prop 71-funded stem cell labs opens

Associated Press
03/10/10 5:05 PM PST

SACRAMENTO, CALIF. — The first of a dozen major laboratories funded in part by California’s voter-approved stem cell initiative is opening in Sacramento.

The UC Davis Institute for Regenerative Cures opened Wednesday. The $62 million institute will bring together 200 scientists and lab technicians and consolidate the university’s stem cell research efforts under one roof.

Research already in progress at UC Davis includes using stem cells for HIV treatments, organ regeneration and injury repair in horses.

The institute received $20 million from bonds authorized by Proposition 71, the California Stem Cell Research and Cures Act of 2004.

Institute director Jan Nolta says UC Davis is moving away from the use of embryonic stem cells in favor of other techniques.



Information from: The Sacramento Bee, http://www.sacbee.com

Read more at the San Francisco Examiner: http://www.sfexaminer.com/local/ap/first-of-dozen-prop-71-funded-stem-cell-labs-opens-87287082.html#ixzz0hpritFs0

JANET JACKSON – It’s time to blow amFAR up!

In CELEBRITIES & STEM CELLS on October 16, 2009 at 3:15 pm


amfAR is proof people have succumbed to AIDS

AIDS Awareness

The Foundation for AIDS Research was founded in 1985 and since they have invested nearly $290 Million on its mission. We are talking about an average of about $10 million per year for 25 years. Yet this diseased killed over 25 million people, with over 33 million infected. A better calculation would be about $10 per fatality or $3 or $4 per causality. We are talking about an organization that spends close to 71% towards its objective of 71 cents to a dollar and I think that is very aggressive and phenomenal.

We are talking about an organization full of celebrities affiliations, yet there is not International Anthem sung in there behalf, there is not concerts in there behalf, there is just a bunch of silent watchers. It is time to blow amfAR up, with the promise of Stem Cell Research, AIDS Research promises to reach a new height. It’s time for a song and a concert, a movie and celebrity promotions on TV and radio. We cannot afford to sit silently and watch people die unnecessarily. We have to show hope, that hope be a reality. The Foundation for AIDS Research does not need celebrity money it needs your time and talents to generate awareness of the current agenda, then the money will follow. What Janet Jackson is doing is honorable and more should follow suit.


In ALL ARTICLES on October 15, 2009 at 3:10 pm



Janet Jackson recently arrived in Milan, Italy to chair at an amfAR charity event, as they try to raise funds and awareness. There are a lot of organizations that operate on the frontlines of the battle against AIDS and are proportionately well funded, providing things like housing, counseling and the essentials to better living.

However, amfAR (The Foundation for AIDS Research) is disproportionately under-funded receiving a small amount of the money spent on AIDS Research. Whereby if there was an intelligence department in AIDS Research they are it, as in over a period about 25 years founded in 1985 they spent about $300 million on their mission. However there were over 25 million deaths due to the complications of AIDS and at least 33 million infected as of this day. People are living longer with AIDS now, but it is still for most a death sentence.

Janet Jackson arrives in Milan, Italy for amfAR Charity event

Yes it is important to serve those underserved in society such as People Living with AIDS, but the only real hope is in finding a cure to eradicate this dreadful disease. And that is the mission of amfAR. I think with the promises of Stem Cell Research there should be a resurgence of enthusiasm and not settling for just treatments that ultimately leads to death, but an actual cure.


There was a recent BUZZ stating that there is a female contraceptive ring that can prevent the transmission of AIDS, so there has been real progress in AIDS research. Hopefully a cure will be found in the life time of the many infected people as of this day.

%d bloggers like this: